The Pharmaceutical Supply Chain, 2013–2023 | Insights | BRG

Many of the same market dynamics observed in our previous publications have continued and even intensified in recent years.

Blaming Patents Won’t Lower Drug Prices – DC Journal - InsideSources

Congress is considering a bill that could deter billions of dollars of medical research investments, undermining U.S. global leadership as a healthcare

Sisco: Don’t tie rare disease patients’ lives to the lowest price

Jill Sisco, president of Acromegaly Community, opposes the Most Favored Nation policy that would limit rare disease patients' access to innovative therapies.

How Tennessee’s PBM law could affect retail pharmacies at large

The law is another step in an escalating national effort to curb vertical integration.

Medicare, Medicaid, and the Hospital Cost Crisis - Americans for Tax Reform

Hospital prices have been increasing steadily while the overall quality of care for the American taxpayer has not. Meanwhile, Americans have been fed the

Richmond physician: Griffith is right to demand greater transparency in little-known federal program

What was meant to be a patient-focused program is now a hospital markup program where large, tax-exempt hospital systems buy discounted drugs, mark them up by as much as 1,000% or more and bill pat…

It’s Time For Congress To Get 340B Out Of Its Blind Spot

When hospitals overcharge insurers for drugs they bought at deep 340B discounts, taxpayers, employers, and insured patients foot the bill.

National Survey Shows a Vast Majority of Americans Want Comprehensive Reform of the 340B Drug...

340B: End the Spread

The 340B Drug Pricing Program (340B) has returned to the spotlight as the Trump admin proposes reforms to how hospitals receive funding.

Opinion: Price controls could prevent the next ‘miracle drug...

Opinion: Decades of costly, high-risk drug research have slashed deaths from diseases like cancer and HIV; the authors argue new price controls could choke off ...